Overview

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Doxorubicin
Liposomal doxorubicin